Germany must change its stem cell law to benefit from this innovative technology
This article was originally published in Clinica
Executive Summary
Germany’s insistence on finding a consensus on embryonic stem cell research and its ban on the use of home-grown cell lines are hampering its ability to keep pace with other high- technology countries in this field. The stakes have been raised even higher of late, as US President Barack Obama has reversed the policy of the Bush era, and lifted the ban on stem cell research funding. But the barriers to success for German researchers in this area are simultaneously legal, ethical and religious in nature.
You may also be interested in...
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.
EMA Acts To Freeze GVK Drugs, Guard Against Shortages
The EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.
EMA Acts To Freeze Drugs Linked to GVK Bio, Guards Against Shortages
EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.